No full text
Article (Scientific journals)
Comment je traite ... le myelome multiple refractaire par thalidomide
Scerbo, F.; Matus, G.; Sautois, Brieuc et al.
2000In Revue Médicale de Liège, 55 (11), p. 970-3
Peer reviewed
 

Files


Full Text
No document available.

Send to



Details



Abstract :
[en] Despite the use of high-dose chemotherapy with autologous hematopoietic stem cell transplantation, multiple myeloma remains largely uncurable. Indeed complete remission rate is about 50% and median survival reaches 5 years without plateau. Recently thalidomide has been identified as a promising agent. We report the clinical story of 2 patients with refractory myeloma that we treated successfully with thalidomide.
Disciplines :
Hematology
Author, co-author :
Scerbo, F.
Matus, G.
Sautois, Brieuc  ;  Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
Fillet, Georges ;  Université de Liège - ULiège > Département des sciences cliniques > Hématologie - Oncologie médicale
Language :
French
Title :
Comment je traite ... le myelome multiple refractaire par thalidomide
Alternative titles :
[en] How I Treat... Refractory Multiple Myeloma with Thalidomide
Publication date :
November 2000
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Volume :
55
Issue :
11
Pages :
970-3
Peer reviewed :
Peer reviewed
Available on ORBi :
since 02 April 2009

Statistics


Number of views
133 (3 by ULiège)
Number of downloads
0 (0 by ULiège)

Scopus citations®
 
0
Scopus citations®
without self-citations
0

Bibliography


Similar publications



Contact ORBi